Soligenix Reports Positive Extended Phase 2a Results for Psoriasis Treatment SGX302 Gel
TL;DR
Soligenix's SGX302 gel shows superior efficacy over its ointment formulation in psoriasis trials, offering investors a potential advantage in the rare disease treatment market.
Soligenix's Phase 2a trial demonstrated SGX302's optimized topical gel formulation improved clinical scores and quality-of-life measures with no drug-related adverse events.
SGX302's non-carcinogenic, non-mutagenic properties could provide a safer therapeutic option for psoriasis patients, improving treatment outcomes and quality of life.
Soligenix's synthetic hypericin gel for psoriasis shows promising results, potentially offering a novel, non-toxic treatment derived from a natural compound.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. reported extended results from its ongoing Phase 2a trial evaluating SGX302, a synthetic hypericin topical gel formulation, for the treatment of mild-to-moderate psoriasis. The biopharmaceutical company, which focuses on rare diseases with unmet medical needs, found the optimized gel formulation was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures.
The extended results included outcomes from an additional cohort treated with the optimized topical gel formulation, with performance comparable to or exceeding results observed with the prior ointment formulation. Clinical measures showing improvement included Investigator Global Assessment and Psoriasis Area and Severity Index scores. These findings support continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis patients.
This development is significant because psoriasis affects millions worldwide, and current treatments often carry risks of carcinogenicity or mutagenicity. The positive safety profile of SGX302, combined with demonstrated efficacy, could provide a safer alternative for long-term management of this chronic condition. The company's Specialized BioTherapeutics business segment is developing synthetic hypericin technology across multiple indications, with HyBryte (SGX301) already showing promise for cutaneous T-cell lymphoma treatment.
Soligenix's broader development pipeline includes expansion of synthetic hypericin into psoriasis, first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behcet's Disease. The company maintains a Public Health Solutions business segment focused on vaccine development, supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The latest news and updates relating to Soligenix are available in the company's newsroom at https://nnw.fm/SNGX. The full press release detailing the Phase 2a results can be viewed at https://nnw.fm/9ngJA. NetworkNewsWire, which distributed the announcement, provides financial news and content distribution services as part of the Dynamic Brand Portfolio, with more information available at https://www.NetworkNewsWire.com.
Curated from InvestorBrandNetwork (IBN)
